| Introducing Oncotarget |
|
https://doi.org/10.18632/oncotarget.101
Mikhail Blagosklonny,
and Andrei Gudkov
|
| 2 |
Shape-shifting and tumor suppression by PLZF
Shape-shifting and tumor suppression by PLZF |
|
https://doi.org/10.18632/oncotarget.102
Robin M. Hobbs,
and Pier Paolo Pandolfi
|
| 3-5 |
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors |
|
https://doi.org/10.18632/oncotarget.103
Stefan Duensing,
and Anette Duensing
|
| 6-8 |
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation
Smooth muscle α-actin is a direct target of PLZF: effects on the cytoskeleton and on susceptibility to oncogenic transformation |
|
https://doi.org/10.18632/oncotarget.104
Jin Shi,
Minghao Sun,
and Peter K. Vogt
|
| 9-21 |
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance |
|
https://doi.org/10.18632/oncotarget.105
Lei Shi,
Siqing Wang,
Maurizio Zangari,
Hongwei Xu,
Thai M. Cao,
Chunjiao Xu,
Yong Wu,
Fang Xiao,
Yinghong Liu,
Ye Yang,
Mohamed Salama,
Guiyuan Li,
Guido Tricot,
and Fenghuang Zhan
|
| 22-33 |
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome |
|
https://doi.org/10.18632/oncotarget.106
Emmanuel Raffoux,
Audrey Cras,
Christian Recher,
Pierre-Yves Boëlle,
Adrienne de Labarthe,
Pascal Turlure,
Jean-Pierre Marolleau,
Oumedaly Reman,
Claude Gardin,
Maud Victor,
Sébastien Maury,
Philippe Rousselot,
Jean-Valère Malfuson,
Odile Maarek,
Marie-Thérèse Daniel,
Pierre Fenaux,
Laurent Degos,
Christine Chomienne,
Sylvie Chevret,
and Hervé Dombret
|
| 34-42 |
The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword
The tumor suppressor p53 connects ribosome biogenesis to cell cycle control: a double-edged sword |
|
https://doi.org/10.18632/oncotarget.107
Michael Hölzel,
Kaspar Burger,
Bastian Mühl,
Mathias Orban,
Markus Kellner,
and Dirk Eick
|
| 43-47 |
ID4: a new player in the cancer arena
ID4: a new player in the cancer arena |
|
https://doi.org/10.18632/oncotarget.108
Stefania Dell’Orso,
Federica Ganci,
Sabrina Strano,
Giovanni Blandino,
and Giulia Fontemaggi
|
| 48-58 |
A critical role for the NFkB pathway in multiple myeloma
A critical role for the NFkB pathway in multiple myeloma |
|
https://doi.org/10.18632/oncotarget.109
Yulia N. Demchenko,
and W. Michael Kuehl
|
| 59-68 |
Targeting TOR dependence in cancer
Targeting TOR dependence in cancer |
|
https://doi.org/10.18632/oncotarget.110
Matthew R. Janes,
and David A. Fruman
|
| 69-76 |
